NICE Technology Appraisal Guidance No 70 - Use of imatinib for
chronic myeloid leukaemia
NICE Technology
Appraisal Guidance No 70 - Use of imatinib for chronic myeloid
leukaemia
This guidance has been partially updated by NICE technology appraisal
guidance 241 (TA241) Dasatinib, high-dose imatinib and
nilotinib for the treatment of imatinib-resistant chronic myeloid
leukaemia (CML) (part review of NICE technology appraisal guidance
70), and dasatinib and nilotinib for people with CML for whom
treatment with imatinib has failed because of intolerance
The following NICE Guidance has been considered by NHS Quality
Improvement Scotland through its revised procedure of processing of
NICE Guidance.
NICE Technology Appraisal Guidance No 70 - Use of imatinib for
chronic myeloid leukaemia (this guidance replaces Technology
Appraisal Guidance No 50 issued in October 2002)
NHSScotland should note that:
No important differences were identified for this NICE Guidance,
and NHS Quality Improvement Scotland advises that it is as valid
for Scotland as for England and Wales.
NHSScotland should take account of this NICE Guidance and NHS
Quality Improvement Scotland advice in its planning, funding and
provision of services to ensure that recommended drugs or
treatments are made available to meet clinical need.
NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
No other publication on the NICE Guidance will be issued by NHS
Quality Improvement Scotland.
Hard copies of the NICE Guidance are available from NHS Quality
Improvement Scotland (contact Tracey Smiley, tel 0141 225 6993 or
tsmiley@htbs.org.uk) and
all NICE Guidance and NHS Quality Improvement Scotland advice is
available on this website.
Published Date: 22 October 2003
